SPARC

Sun Pharma Advanced Research Company Balance Sheet

₹195.51-0.70%
Market cap
₹6,345 crore
P/E
4.0
P/B
4.74
ROE
276.9%
Dividend yield
1.20%

As of Mar 2022, Sun Pharma Advanced Research Company had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 7,553.06% from Mar 2023.

Sun Pharma Advanced Research Company balance sheet

As at each financial year end, newest first. H1 = half-year.

Sun Pharma Advanced Research Company balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital50032.4532.4532.4532.45
Reserves8,500-1,592-1,979-2,322-766
Borrowings1,20015.6857.66265558
Other liabilities3,500302332287274
Total liabilities13,7008305153362,171
Fixed assets6,50010910999.2685.68
Capital work in progress400100100100100
Investments2,50016610367.11434
Other assets4,300249155101651
Total assets13,7008305153362,171

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Sun Pharma Advanced Research Company balance sheet — frequently asked questions

What is the total debt of Sun Pharma Advanced Research Company?

Sun Pharma Advanced Research Company reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹15.68 crore as of Mar 2023.

What is Sun Pharma Advanced Research Company's debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Sun Pharma Advanced Research Company's debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Sun Pharma Advanced Research Company's total assets?

Sun Pharma Advanced Research Company's total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Sun Pharma Advanced Research Company With ATS

Track SPARC live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.